# FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer

> **NCT05627635** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 20 (actual)

## Conditions studied

- Metastatic Colon Adenocarcinoma
- Metastatic Colorectal Adenocarcinoma
- Metastatic Microsatellite Stable Colorectal Carcinoma
- Metastatic Rectal Adenocarcinoma
- Stage IV Colon Cancer AJCC v8
- Stage IV Colorectal Cancer AJCC v8
- Stage IV Rectal Cancer AJCC v8

## Interventions

- **BIOLOGICAL:** Balstilimab
- **BIOLOGICAL:** Bevacizumab
- **PROCEDURE:** Biospecimen Collection
- **BIOLOGICAL:** Botensilimab
- **PROCEDURE:** Computed Tomography
- **DRUG:** Fluorouracil
- **DRUG:** Leucovorin Calcium
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Oxaliplatin
- **PROCEDURE:** Positron Emission Tomography
- **PROCEDURE:** X-Ray Imaging

## Key facts

- **NCT ID:** NCT05627635
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-03
- **Primary completion:** 2026-06-23
- **Final completion:** 2026-06-23
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-11-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05627635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05627635, "FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT05627635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*